Yes, absolutely. There's surveillance of resistance and surveillance of use. They are slightly different. We tend to lump them together. I think there is a need for both. Certainly in our workshop we were in agreement that we would like to see surveillance for a better understanding of what antimicrobials are used, where they're used, and why they're used, as opposed to the primary data we now have, which is what is being sold at the wholesale level. You don't know the specific implications of that. I think better data needs to be there so that we can measure what's being used. If we target reductions, we'll know we're making reductions, for what reasons, and where they're at.
There absolutely is a need for improved surveillance of use at some level on the chain beyond the wholesale level, such as at the veterinary use or end-user level.